Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27087776 | 0.88 | LMNA (0.47) | MAPK1CA1CA12CA9LMNA | |
| SCHEMBL5367354 | 0.84 | AAK1 (0.46) | MAPK1CA1CA12CA9LMNA | |
| SCHEMBL2105999 | 0.82 | MAPT (0.56) | MAPK1TSHRCA1CA12CA9 | |
| SCHEMBL16069602 | 0.82 | ATM (0.47) | TSHRCA1CA12CA9LMNA | |
| SCHEMBL13654181 | 0.81 | ALDH1A1 (0.44) | CA1CA12CA9LMNAMAPT | |
| SCHEMBL5235060 | 0.81 | ALDH1A1 (0.46) | MAPK1TSHRCA1CA12CA9 | |
| SCHEMBL229029 | 0.81 | CA12 (0.44) | MAPK1CA1CA12CA9LMNA | |
| SCHEMBL31601668 | 0.80 | MAPT (0.44) | CA1CA12CA9MAPTHTT | |
| SCHEMBL5239876 | 0.79 | CA12 (0.43) | MAPK1CA1CA12CA9LMNA | |
| SCHEMBL21603046 | 0.79 | MAPK1 (0.46) | MAPK1TSHRCA1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828378-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-11-28 | — | — | US | disclosed |
| EP-3009436-A1 | KINASE INHIBITORS AND METHODS OF USE | Intellikine, LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20160024099-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2016-01-28 | — | — | US | disclosed |
| EP-2313414-B1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-9096611-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096611-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | PIK3CA, MTOR, PDPK1 | MAPK1 267/4885TSHR 3864/4885CA1 4184/4885 |
| US-20160024099-A1 | KINASE INHIBITORS AND METHODS OF USE | PIK3CA, MTOR, PDPK1 | MAPK1 267/4885TSHR 3864/4885CA1 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.